Published in Cancer Res on July 15, 1998
A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma. Medicine (Baltimore) (2015) 1.49
Expression of galectins in cancer: a critical review. Glycoconj J (2004) 1.28
ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg (2005) 1.27
My approach to oncocytic tumours of the thyroid. J Clin Pathol (2004) 1.15
Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol (2010) 1.14
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci (2007) 1.11
Galectins as cancer biomarkers. Cancers (Basel) (2010) 1.08
Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J (2004) 1.08
Galectin genes: regulation of expression. Glycoconj J (2004) 1.02
Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol (2011) 1.02
What is New on Thyroid Cancer Biomarkers. Biomark Insights (2008) 0.91
Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation (2009) 0.90
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer (2006) 0.90
Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer (2005) 0.90
Expression of galectin-7 is induced in breast cancer cells by mutant p53. PLoS One (2013) 0.88
Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch (2004) 0.85
The Role of Parafibromin, Galectin-3, HBME-1, and Ki-67 in the Differential Diagnosis of Parathyroid Tumors. Oman Med J (2015) 0.82
Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol (2010) 0.82
Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal (2009) 0.81
Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit (2015) 0.81
Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch (2004) 0.81
Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr (2014) 0.80
Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy. Curr Genomics (2011) 0.80
Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. J Clin Diagn Res (2015) 0.77
Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors. Cell Death Discov (2015) 0.77
Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark. World J Surg (2009) 0.77
Galectin-3 and Cyclin D3 Immunohistochemistry and Tumor Dimensions Are Useful in Distinguishing Follicular Oncocytic Carcinomas from Oncocytic Adenomas of the Thyroid. Int J Endocrinol (2015) 0.75
Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms. J Clin Diagn Res (2016) 0.75
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2003) 3.33
A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab (2000) 2.67
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest (2006) 2.53
Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ (1997) 2.21
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem (1999) 1.89
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol (2004) 1.62
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas) J Clin Endocrinol Metab (1994) 1.58
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol (2001) 1.50
Cold snare excision of small colorectal polyps. Gastrointest Endosc (1992) 1.46
Different patterns of steroid secretion in patients with adrenal incidentaloma. J Clin Endocrinol Metab (1996) 1.43
Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest (2003) 1.40
Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH Registry. J Endocrinol Invest (2006) 1.39
Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. J Clin Endocrinol Metab (1997) 1.39
Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int (2009) 1.36
Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer (2005) 1.14
Short term ethanol ingestion can affect the testicular response to single-dose human chorionic gonadotropin in normal subjects. J Endocrinol Invest (1986) 1.12
Management of neuroendocrine differentiated breast carcinoma. Breast (2004) 1.08
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab (2000) 1.05
Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer (2001) 1.05
Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer (1993) 1.03
[Incidence and socioeconomic burden of hip fractures in Italy]. Reumatismo (2005) 1.02
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis (2008) 1.02
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer (2005) 1.01
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer (2005) 1.00
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst (1996) 0.99
Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther (1978) 0.99
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer (1998) 0.98
Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol (2001) 0.98
Endoscopic diagnosis and treatment of gastric bezoars. Gastrointest Endosc (1998) 0.98
Serum angiotensin converting enzyme (ACE) in silicosis. Eur J Respir Dis (1984) 0.98
Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med (2010) 0.98
Natural killer cell activity and sensitivity to positive and negative modulation in uncomplicated obese subjects: relationships to leptin and diet composition. Int J Obes Relat Metab Disord (2004) 0.97
The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. Clin Endocrinol (Oxf) (2001) 0.96
Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int (2004) 0.95
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol (2001) 0.95
Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res (1994) 0.94
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol (1994) 0.94
Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest (1995) 0.93
Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest (2004) 0.92
Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. Eur J Appl Physiol (2004) 0.92
Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology (2001) 0.91
Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab (2001) 0.91
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer (1996) 0.91
Once-a-day neurally stimulated and basal ACTH secretion phases in man and their response to corticoid inhibition. J Clin Endocrinol Metab (1969) 0.89
Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital J Gastroenterol Hepatol (1997) 0.88
Congenital syphilis in Italy. Sex Transm Infect (2007) 0.88
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol (2001) 0.86
Subclinical Cushing's syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) (1998) 0.86
Tubercular involvement of the thyroid gland: a report of two cases. Horm Res (1999) 0.86
[Hemoperitoneum caused by cavernous angioma of the omentum]. Minerva Chir (1989) 0.85
Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer (2000) 0.85
p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer (2001) 0.85
Circadian variations of thyrotropin bioactivity in normal subjects and patients with primary hypothyroidism. J Clin Endocrinol Metab (1995) 0.85
Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol (1996) 0.85
Serum interleukin-6 response to elective total hip replacement surgery. Int Orthop (2006) 0.84
Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment. Calcif Tissue Int (1993) 0.84
Recurrent thromboembolism as a hallmark of Cushing's syndrome. J Endocrinol Invest (1997) 0.84
Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. Horm Metab Res (1995) 0.84
Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers (2003) 0.83
Effect of cyproterone acetate therapy on gonadotropin response to synthetic luteinizing hormone-releasing hormone (LRH) in girls with idiopathic precocious puberty. J Clin Endocrinol Metab (1976) 0.83
Inhibition by cortisol of human natural killer (NK) cell activity. J Steroid Biochem (1987) 0.83
Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) (2001) 0.82
Polyvariant mutant CFTR genes in patients with chronic pancreatitis. Clin Genet (1999) 0.82
[Nylon fiber and possible lung pathology]. Med Lav (1996) 0.82
Role of platelet activating factor in acute pancreatitis induced by lipopolysaccharides in rabbits. Eur J Pharmacol (1994) 0.81
Effect of synthetic luteinizing hormone releasing hormone (LH-RH) on the release of gonadotropins in Cushing's disease. J Clin Endocrinol Metab (1975) 0.81
Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast. Cancer Res (1992) 0.81
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol (2001) 0.81
Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer (1994) 0.81
Multifrequency rhythms of immunological functions. Chronobiologia (1988) 0.81
Interplay in vitro between ACTH, beta-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity. Brain Behav Immun (1993) 0.81
Adult fibrosing colonopathy associated with mesalazine treatment. Am J Gastroenterol (2001) 0.80
Impulsive and basal ACTH secretion phases in normal subjects, in obese subjects with signs of adrenocortical hyperfunction and in hyperthyroid patients. J Clin Endocrinol Metab (1970) 0.80
Safe switch to beta-interferon treatment of chronic hepatitis C after alpha-interferon-induced autoimmune thrombocytopenia. J Hepatol (1996) 0.80
Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome. J Endocrinol Invest (2003) 0.80
Corticotroph axis sensitivity after exercise: comparison between elite athletes and sedentary subjects. J Endocrinol Invest (2007) 0.80